Gynäkologie und gynäkologische Onkologie –
Publikationen

Aktuelle Publikationen

Peer-reviewed articles since 2020       

• Pubmed

K. Riecke, V. Müller, T. Neunhöffer, T.-W. Park-Simon, R. Weide, A. Polasik, M. Schmidt, J. Puppe, C. Mundhenke, K. Lübbe, T. Hesse, M. Thill, R. Wuerstlein, C. Denkert, T. Decker, T. Fehm, V. Nekljudova, J. Rey, S. Loibl, E. Laakmann, I. Witzel
Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registry
ESMO Open. 2023 Apr 17;8(3):101213. doi: 10.1016/j.esmoop.2023.101213. Online ahead of print.PMID: 37075697 Free article.

E. Laakmann, I. Witzel, T. Neunhöffer, T.-W. Park-Simon, R. Weide, K. Riecke , A. Polasik , M. Schmidt , J. Puppe , C. Mundhenke , K. Lübbe , T. Hesse, M. Thill, D.-M. Zahm, C. Denkert, T. Fehm, V. Nekljudova, J. Rey, S. Loibl, V. Müller
Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry
ESMO Open. 2022 Jun;7(3):100495. doi: 10.1016/j.esmoop.2022.100495. Epub 2022 May 30.PMID: 35653983 Free PMC article.

Riecke K, Müller V, Weide R, Schmidt M, Park-Simon TW, Möbus V, Mundhenke C, Polasik A, Lübbe K, Hesse T, Laakmann E, Thill M, A Fasching P, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Witzel I.
Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry-Comparison of Three Different GPA Prognostic Scores.
Cancers (Basel).2021 Feb 17;13(4):844. doi: 10.3390/cancers13040844. PMID: 33671376; PMCID: PMC7922206

Laakmann E, Witzel I, Neunhöffer T, Weide R, Schmidt M, Park-Simon T-W, Möbus V, Mundhenke C, Polasik A, Lübbe K, Hesse T, Riecke K, Thill M, Fasching P, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Müller V
Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases
Cancers (Basel). 2020 Sep 28;12(10):2787. doi: 10.3390/cancers12102787.PMID: 32998430 Free PMC article.

Congress contribution since 2020

ESMO 2022, Sept. 09-13, 2022:
E. Laakmann, K. Riecke, T. Neunhöffer, T. Park-Simon, R. Weide, A. Polasik, M. Schmidt, J. Puppe, P.A. Fasching, T. Hesse, T. Decker, C. Denkert, T.N. Fehm, V. Nekljudova, J. Rey, S. Loibl, V. Mueller, I. Witzel
Long-term survival of HER2-positive breast cancer patients with brain metastases: Subanalysis of the BMBC Registry
Annals of Oncology (2022), Volume 33, Supplement 7, S88-S121

ESMO-Breast Cancer, May 03-05, 2022:
K. Riecke, E. Laakmann, T. Neunhöffer, T. Park-Simon, R. Weide, M. Schmidt, A. Polasik, J. Puppe, C. Mundhenke, K. Lübbe, T. Hesse, M. Thill, D. Zahm, C. Denkert, T. Fehm, V. Nekljudova, J. Rey, S. Loib, V. Müller, I. Witzel
Long-term survival of breast cancer patients with brain metastases: Subanalysis of the BMBC Registry
Annals of Oncology (2022), Volume 33, Supplement 3: S194-S223

ESMO 2021, Sept. 16-21, 2021:
M. Schmidt, C. Jackisch, T. Hesse, O. Hoffmann, B. J. Heinrich, T.-W. Park-Simon, E.-M. Grischke, R. Weide, H. Mueller-Huesmann, M. Welslau,J. Wu, H. Schmitz, C. Engelbrecht, H.-J. Lück
Incidence and resolution of eribulin-induced peripheral neuropathy (IRENE) in patients with locally advanced or metastatic breast cancer
Annals of Oncology (2021),Volume 32, Supplement 5, S496-497

40. Jahrestagung der Deutschen Gesellschaft für Senologie, 17.-21.09.2021:
Laakmann E, Witzel I, Neunhöffer T, Park-Simon TW , Weide R , Riecke K , Polasik A , Puppe J, Mundhenke C , Lübbe K , Hesse T , Thill M, Zahm D, Denkert C, Fehm T, Nekljudova V, Rey J,
Loibl S, Müller V
Characteristics of patients with brain metastases from HER2-positive breast cancer
Senologie (2021); 18: e1–e50, DOI 10.1055/s-0041-1730190,oral presentation

ESMO-Breast Cancer, May 05-08, 2021, Virtual Meeting:
E. Laakmann, I. Witzel, T. Neunhöffer, T. Park-Simon, R. Weide, K. Riecke, A. Polasik, M. Schmidt, J. Puppe, C. Mundhenke, K. Lübbe, T. Hesse, M. Thill, D. Zahm, C. Denkert, T. Fehm, V. Nekljudova, J. Rey, S. Loibl, V. Mueller
Characteristics of patients with brain metastases from HER2-positive breast cancer
Annals ofOncology (2021) 32 (suppl_2): S60-S78. 10.1016/annonc/annonc508,oral presentation

SABCS: San Antonio Breast Cancer Symposium, December 8-11, 2020, Virtual Meeting:
Wöckel A, Basiora P, Bohlmann M, Decker T, Falbrede J, Fasching P, Forstbauer H, Hesse T, Hoffmann O, Jackisch C, Kaczerowsky A, Lorenz R, Lüdtke-Heckenkamp K, Lüftner D, Marmé F, Mueller T, Mundhenke C, Nusch A, Petersen V, Prange-Krex G, Reimer T, Resch T, Roos C, Tomé O, and Weishap A
Real-world efficacy of ribociclib + aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Second interim analysis from the RIBANNA study
Cancer Research 2020, Feb. (80) (4 Supplement) P1-19-33

ESMO-Breast Cancer, May 23-24, 2020, Virtual Meeting:
Riecke K, Mueller V, Neunhöffer T, Weide R, Schmidt M, Park-Simon T-W, Mundhenke C, Polasik A, Hesse T, Lübbe K, Laakmann E, Thill M, Fasching P, Denkert D, Fehm T, Nekljudova V, Rey J, Loibl S, Witzel I
Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry: Comparison of three different prognostic scores
Annals of Oncology 2020, Volume 31, Supplement 2, S70, poster,

EBCC: European Breast Cancer Conference 2020, October 2-3, 2020, Virtual Meeting:
Laakmann E, Witzel I, Neunhöffer T, Weide R, Schmidt M, Park-Simon T-W, Möbus V, Mundhenke C, Polasik A, Lübbe K, Hesse T, Riecke K, Thill M, Fasching P, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Müller V
Characteristics and clinical outcome of breast cancer patients with asymptomatic brain metastases.
Eur J Cancer 2020; Vol 138, S19, poster

DGGG: 63. Kongress der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe 2020, October 7-9, 2020, Virtual Meeting: Riecke K, Mueller V, Neunhöffer T, Weide R, Schmidt M, Park-Simon T-W, Mundhenke C, Polasik A, Hesse T, Lübbe K, Laakmann E, Thill M, Fasching P, Denkert D, Fehm T, Nekljudova V, Rey J, Loibl S, Witzel I
Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry – comparison of three different prognostic scores. 
Geburtshilfe Frauenheilkd 2020; 80(10): e89, DOI:10.1055/s-0040-1717201, oral presentation

Certified online trainings (CME)

Dall P, Banys-Paluchowski M, Finas D, Hesse T, Hönig A, Park-Simon T, Puppe J, Seitz S
Die drei CDK4/6-Hemmer beim metastasierten und lokal fortgeschrittenen Mammakarzinom – Gibt es klinisch relevante Unterschiede?
07/22-07/23: https://cme.medlearning.de/novartis/mammakarzinom_cdk_4_6/index.htm

Case reports since 2020

Hesse T,
Fallbeispiel “Hoher Leidensdruck durch großes Axillarezidiv”
Der Onkologe (05/2021), Band 27, Heft 5, Seite 4

Ältere Publikationen (2019 und älter)

Gottschick C, Raupach-Rosin H, Langer S, Hassan L, Horn J, Dorendorf E, Caputo M, Bittner M, Beier L, Rübsamen N, Schlinkmann K, Zoch B, Guzman CA, Hansen G, Heselich V, Holzapfel E, Hübner J, Pietschmann T, Pieper DH, Pletz M, Riese P, Schmidt-Pokrzywniak A, Hartwig S, von Kaisenberg C, Aydogdu M, Buhles M, Dressler F, Eberl W, Haase R, Edler von Koch F, Feidicker S, Frambach T, Franz HGB, Guthmann F, Koch HG, Seeger S, Oberhoff C, Pauker W, Petry KU, Schild RL, Tchirikov M, Röhrig E, Karch A, Mikolajczyk R. Cohort Profile: The LoewenKIDS Study - life-course perspective on infections, the microbiome and the development of the immune system in early childhood. Int J Epidemiol. 2019 Aug 1;48(4):1042-1043h. doi: 10.1093/ije/dyz001. Erratum in: Int J Epidemiol. 2019 Aug 1;48(4):1382-1383. PMID: 30815674; PMCID: PMC7108547.

Gottschick C, Raupach-Rosin H, Langer S, Hassan L, Horn J, Dorendorf E, Caputo M, Bittner M, Beier L, Rübsamen N, Schlinkmann K, Zoch B, Guzman CA, Hansen G, Heselich V, Holzapfel E, Hübner J, Pietschmann T, Pieper DH, Pletz M, Riese P, Schmidt-Pokrzywniak A, Hartwig S, von Kaisenberg C, Aydogdu M, Buhles M, Dressler F, Eberl W, Haase R, von Koch FE, Feidicker S, Frambach T, Franz HGB, Guthmann F, Koch HG, Seeger S, Oberhoff C, Pauker W, Petry KU, Schild RL, Tchirikov M, Röhrig E, Karch A, Mikolajczyk R. Cohort profile: The LoewenKIDS Study - life-course perspective on infections, the microbiome and the development of the immune system in early childhood. Int J Epidemiol. 2019 Aug 1;48(4):1382-1383. doi: 10.1093/ije/dyz069. Erratum for: Int J Epidemiol. 2019 Aug 1;48(4):1042-1043h. PMID: 30938437; PMCID: PMC7263872.

Witzel ID, Riecke K, Laakmann E, Weide R, Neunhoeffer T, Park-Simon T-W, Schmidt M, Fasching PA, Hesse T, Polasik A, Mohrmann S, Würschmidt F, Schem C, Bechtner C, Würstlein R, Fehm T, Möbus V, Burchardi N, Loibl S and Müller V
Validation of different prognostic scores in breast cancer patients with brain metastases of the BMBC registry (GBG-79)
Cancer Research 2019, Feb. (79) (4 Supplement) P4-08-26; DOI: 10.1158/1538-7445 SABCS18-P4-08-26 

Witzel ID, Laakmann E, Weide R, Neunhöffer T, Park-Simon T-W, Schmidt M, Fasching PA, Hesse T, Polasik A, Mohrmann S, Würschmidt F, Schem C, Bechtner C, Würstlein R, Fehm T, Möbus V, Burchardi N, Loibl S and Müller V
Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry
European Journal of Cancer 102 (07/2018) 1e9; DOI: 10.1016/j.ejca.2018.07.004

Runnebaum I, Reichert D, Ringsdorf U, Kuther M, Hesse T, Sehouli J, Wimberger P.: Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study.
J Cancer Res Clin Oncol. 2018 Jun;144(6):1185-1195.

Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Hesse T, Pivot X; SafeHer Study Group: Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
Eur J Cancer. 2017 Sep;82:237-246. doi: 10.1016/j.ejca.2017.05.010. Epub 2017 Jun 16.

V. Pauker (Bremen, Germany) “Fertility preservation in women with cancer” XXX Jubilee international Congress with Endoscopic Course: New technologies for Diagnosis and Treatment of Gynecologic Diseases. Report. Moscow, June 6–9, 2017

Reichert D, Wimberger P, Ringsdorf U, Hesse T, Runnebaum I;
An observational, multicenter, prospective study of trabectedin plus
pegylated liposomal doxorubicin (PLD) in patients with platinumsensitive
recurrent ovarian cancer (PSROC)
Annals of Oncology. 2017;28 (suppl 5; 967P)

Payanidi Yu.G., Zhordania K.I., Pauker V., Selchuk V.Yu., Kazubskaya T.P. Multiple primary malignant neoplasms of female reproductive system organs and of the colon.Oncogynecology. 2016 (1):18-23, Moscow

Payanidi Yu.G., Zhordania K.I., Pauker V., Selchuk V.Yu., Kazubskaya T.P. Polyneoplasia of female reproductive organs and heredity. Akusherstvo i ginekologiya/Obstetrics and Gynecology. 2016; (9): 68-72. 

Payanidi Yulia G., Doctor of Medicine, Ph.D. in Medical Sciences, Gynecologic Oncology, N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia. 115478, Russia, Moscow, Kashirskoe sh. 24
Kirill I. Zhordania, Doctor of Medicine, Ph.D. in Medical Sciences, Gynecologic Oncology, N.N. Blokhin Russian Cancer Research Center. 115478, Russia, Moscow, Kashirskoe sh. 24.

Shelepova V.M.1, Dzhanian I.A. 1, Komarov I.G. 1, Pauker V. 2 The role of tumor markers in the diagnosis of multiple primary malignant neoplasms of the colon and the ovaries. Oncogynecology. 2016 (2):71-77, Moscow

Laakmann E, Witzel I, Scriba V, Grzyska U, Zu Eulenburg C, Burchardi N, Hesse T, Würschmidt F, Fehm T, Möbus V, von Minckwitz G, Loibl S, Park-Simon TW, Mueller V: Radiological Patterns of Brain Metastases in Breast Cancer Patients: A Subproject of the German Brain Metastases in Breast Cancer (BMBC) Registry.
Int J Mol Sci. 2016 Sep 23;17(10). pii: E1615. doi: 10.3390/ijms17101615. PMID: 27669228

Mueller V, Loibl S, Laakmann E, Augustin D, Flock F, Dohmen H, Strittmatter H, Frank M, Hesse T, Ignatov A, Kuehn T, Park-Simon T, Schmidt M, Wuerschmidt F, Fehm T, Moebus V, Von Minckwitz G, Burchardi N, Witzel I:
Brain Metastases in Breast Cancer Network Germany (BMBC, GBG 79): Treatment patterns and clinical outcome of more than 1000 patients with brain metastases from breast cancer.
J Clin Oncol 34, 2016 (suppl; abstr 2070)

Laakmann E, Scriba V, Grzyska U, Hesse T, Würschmidt F, Park-Simon T, Loibl S, von Minckwitz G, Fehm T, Möbus V, Schmalfeldt B, Witzel I, Müller V:
Lokalisation von Hirnmetastasen beim metastasierten Mammakarzinom in Abhängigkeit von Tumorbiologie und Behandlung – ein Subprojekt des nationalen Registers BMBC Senologie - Zeitschrift für Mammadiagnostik und -therapie 2016; 13 - A76.
DOI: 10.1055/s-0036-1583397
                                                
Laakmann E, Witzel I, Fehm T, Hesse T, von Minckwitz G, Möbus V, Park-Simon T, Neunhöffer T, Schmidt M, Loibl S, Müller V:
Brain Metastases in Breast Cancer Network Germany (BMBC, GBG 79): The introduction of the multicenter register and analysis of patient data.
Oncol Res Treat 2016;39 (suppl 1):1–175.

V. Pauker (Germany) “Ovarian cancer, the eternal question of how to diagnose, how to treat, how to control? Report. October 20-21, 2015 V Conference "OSORS", Moscow

Hanker L, Hitschold T, Grafe A, Förster F, Schröder J, Janssen J, Reichert D, Keitel S, Hesse T:
Efficacy of trastuzumab re-therapy in the clinical routine of HER2-positive breast cancer patients who relapsed after completed anti-HER2 (neo)adjuvant therapy – 5th interim analysis of the national non-interventional study (NIS) ML21589
SABCS 2015; P4-14-08.

Witzel I, Loibl S, Laakmann E, Augustin D, Flock F, Dohmen H-H, Durmus G, Frank M, Hesse T, Ignatov A, Kühn T, Neunhöffer T, Park-Simon T-W, Schmidt M, Stefek A, Weide R, Würschmidt F, Fehm T, Moebus V, von Minckwitz G, Burchardi N, Mueller V:
Brain metastases in breast cancer network Germany (BMBC, GBG 79): First analysis of 1004 patients from the multicenter registry
SABCS 2015; P6-17-08.

E. Laakmann, V. Scriba, U. Grzyska, T. Hesse, F. Würschmidt, T. Park-Simon ,  I. Witzel, V. Müller:

Hirnmetastasierungsmuster beim metastasierten Mammakarzinom in Abhängigkeit von der Tumorbiologie:  Subanalyse im Rahmen des BMBC Registers
Publikation im Abstract-Band des 7. Wissenschaftliches Symposium der Kommission
Translationale Forschung der AGO, 22.10. – 23.10.2015, Düsseldorf

I. Diel, T. Hamm, D. Hecker, T. Hesse, C. Kluike, A. Nusch, R. Rohrberg, S. Rueckinger, J. Schilling, A. Seitz, P. Spiegelhalder:
X-TREME: Interim analysis from a German open-label, observational study for treatment persistence with denosumab in routine use in adults with bone metastases secondary to solid tumors
European Journal of Cancer, 2015; vol. 51, suppl 3, abstr.1522

Hanker L, Hitschold T, Grafe A, Förster F, Schröder J, Janssen J, Reichert D, Wohlfarth T, Hesse T:
Wirksamkeit erneuter Anti-HER2-Therapie mit Herceptin® in der klinischen Routine bei erstem Rezidiv und/oder erster Metastasierung des HER2-positiven Mammakarzinom 4. Interimanalyse der nichtinterventionellen Studie ML21589 
Senologie - Zeitschrift für Mammadiagnostik und -therapie 2014;11-A50,DOI:10.1055/s-0034-1375409

Pauker V. Oncological Diseases and Pregnancy. Oncogynecology. 2014 (4):59-67, Moscow
Hospital of Bremen Nord, Germany

Pauker V. Basic principles of chemotherapy during pregnancy VI Russian-German Congress: Modern technologies of obstetrics and gynecology in solving problems of demographic security. Report. Collection of materials. -S.105-114. Kaliningrad, 2014, April 25-26

Hanker L, Hitschold T, Grafe A, Förster F, Schröder J, Janssen J, Hesse T:
Efficacy of anti-HER2 retherapy with trastuzumab at first relapse and/or first occurrence of metastases of HER2-positive breast cancer in clinical routine - 4th interim analysis of the non-interventional study ML21589
Annals of Oncology. 2014;25 (suppl 4; 400P)

Pauker V. Chemotherapy during pregnancy - is it possible? The situation in Germany, Europe and the world. Report. VII International Congress of Reproductive Medicine. Moscow, 2013, January 21-24.

Pauker V. Chemotherapy during pregnancy: European experience, opportunities, prospects. Report. International Congress, "New technologies in obstetrics, gynecology, perinatology and reproductive medicine." April 16-19, 2013, Novosibirsk.

Pauker W.A., Shmakov R.G. Cancer and pregnancy. Akusherstvo i ginekologiya/Obstetrics and Gynecology. 2013; (11): 13-18.

Hospital of Bremen Nord, Germany; Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, Moscow

Hanker L, Hitschold T, Hesse T, Grafe A, Förster F, Schröder J, et al.:

Efficacy of trastuzumab re-therapy in routine treatment of HER2-positive breast cancer patients who relapsed after completed (neo-)adjuvant anti-HER2 therapy.
J Clin Oncol. 2013;31(suppl; abstr 602)

Schmidt M, Hesse T, Lerchenmuller C, Diel I:
Ibandronate Shows Marked Pain Relief and a Favorable Renal Safety Profile — Final Results of a Large-Scale Non Interventional Study in Breast Cancer Patients with Metastatic Bone Disease
Cancer Research. 2010; 70(24 Suppl):nr P1-13-02.

Diel I, Hesse T, Lerchenmuller C, Schmidt M:
Ibandronate in the treatment of patients (pts) with breast cancer (BC) with metastatic bone disease (MBD): Final results of a large-scale noninterventional study.
J Clin Oncol 28:15s, 2010 (suppl; abstr 1026)

Siedentopf  F, Göhler T, Nusch A, Hesse T, et al.:
Real-life usage of capecitabine for advanced breast cancer (ABC) in Germany: efficacy and safety results from a large (n = 870) non-interventional study
EJC Supplements 2009 Sep; 7(2):281-281. DOI: 10.1016/S1359-6349(09)70962-0

Schmidt, M; Hesse, T; Kuehnle, H et al.:
Ibandronate Shows Marked Pain Relief and a Favorable Renal Safety Profile - Updated Results of a Non Interventional Study in Breast Cancer Patients with Metastatic Bone Disease
Cancer Research. 2009, 69 (24 Suppl): 573-573S

Siedentopf  F, Göhler T, Nusch A, Hesse T, et al.:
Capecitabine in the routine treatment of advanced breast cancer: results from a non-interventional observational study in 876 patients.
Onkologie - International Journal for Cancer Research and Treatment. 2009 Nov; 32(11):631-636

Hesse T, Hussmann N, Vogt S, Meden H:
Applikationsfertige Zubereitung von Trastuzumab in der Arztpraxis und Ambulanz oder der Apotheke? Praktische und juristische Aspekte für den Regressfall 
Senologie - Zeitschrift für Mammadiagnostik und -therapie 2007; 4 - A47
DOI:10.1055/s-2007-982952

Hesse T, Wiese A, Meinhardt A, Schlichting C, Parthey G:
Betreuung von Patientinnen mit metastasiertem Mammakarzinom – Palliativmedizin in der gynäkologischen Onkologie
Publikation im Abstract-Band der 6. Wissenschaftlichen Tagung der PSO, „Psychoonkologie und Palliativmedizin“ 06.– 08. Dezember 2007, Hamburg, Poster P10

Hesse T, Hussmann N, Kozianka W, Meden H:
Adjuvante immunologische Therapie beim Mammaarzinom: praktische und juristische Aspekte der Off-label-use-Behandlung mit Trastuzumab
Publikation im Abstract-Band der 122. Tagung der NGGG, 31.06. – 02.07.2006, Oldenburg, Poster 29

Hesse T, Klinke S, Wischnewsky M, Meden H:
Wirksamkeit und Verträglichkeit der wöchentlichen Therapie mit Trastuzumab (Herceptin®) und Vinorelbin (Navelbine®) nach vorangegangener Doxetaxel-Therapie bei Patientinnen mit metastasierten Mammakarzinom
Publikation auf CD Kongreß-Abstracts des 54. Kongresses der DGGG, 10. – 14.09.2002, Düsseldorf, Poster PB 01.09

Hesse T, Klinke S, Wischnewsky M, Meden H:
Wirksamkeit und Verträglichkeit der wöchentlichen Therapie mit Trastuzumab (Herceptin®) und Vinorelbin (Navelbine®) nach vorangegangener Doxetaxel-Therapie bei Patientinnen mit metastasierten Mammakarzinom
Publikation im Abstract-Band der 118. Tagung der NGGG, 31.05.– 02.06.2002, Hamburg, Poster P95

Hesse T, Klinke S, Wischnewsky M, Meden H:
Wirksamkeit und Verträglichkeit der wöchentlichen Therapie mit Trastuzumab (Herceptin®) und Vinorelbin (Navelbine®) nach vorangegangener Doxetaxel-Therapie bei Patientinnen mit metastasierten Mammakarzinom
Publikation im Abstract-Band der 117. Tagung der NGGG, 25.-27. Mai 2001, Lübeck, Poster P64

Meden H, Beneke A, Hesse T, Novophashenny I, Wischnewsky M:
Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (Herceptin) plus Docetaxel in patients with metastatic breast cancer: a pilot study.
J Clin Oncol 2001;12(suppl; abstract 1987)

Meden H, Beneke A, Hesse T, Novophashenny I, Wischnewsky M:
Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (Herceptin) plus Docetaxel in patients with metastatic breast cancer: a pilot study.
Anticancer Research. 2001 Mar-Apr; 21(2B):1301-1305.
 
Hesse T, Pfeiffer D, Assert A, Jensen A:
Bestrahlungsinduzierte Apoptose und HPV-Transkription bei Zervixkarzinomzellen 
Publikation im Abstract-Band der 116. Tagung der NGGG, 15. – 17.09.2000, Lüneburg, Vortrag V41